跳至主要内容
临床试验/NCT06198816
NCT06198816招募中不适用

Inflow Improve for Deep Vein ThrombOsis with Ultrasound AcceLerated ThrombOlysis and Venoplasty: a Monocentric, Observational and Prospective Study.

IRCCS San Raffaele1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2024年1月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
50
试验地点
1
主要终点
Clinical Severity Scores

研究概览

简要总结

Aim of the IDOLO study is to investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).

At San Raffaele Hospital (Vascular Surgery Department) will be enrolled 50 patients with lower extremity deep vein thrombosis (who have failed conservative treatment) objectively diagnosed with imaging ≥ 6 months; prior persistent deep vein Thrombosis (DVT) at enrollment evaluation and moderate-severe post-thrombotic syndrome at time of procedure

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient admitted in Vascular Surgery Unit, San Raffaele Hospital, Milan
  • Patients able to sign specific informed consent for the study.
  • Proximal deep vein Thrombosis (iliac vein, common femoral vein, deep femoral vein, and femoral vein) that was objectively diagnosed with duplex imaging and/or venography ≥ 6 months prior to study screening.
  • Persistent chronic deep vein Thrombosis causing restrictive flow, as confirmed by imaging, within 60 days prior to the study procedure.
  • Failed a minimum of 3 consecutive months of conservative treatment (therapeutic anticoagulation and compression stockings).
  • Villalta score ≥8 for the affected limb within 30 days prior to the study procedure

排除标准

  • Treated with mechanical thrombectomy within 2 weeks of the study thrombolysis procedure.
  • Treated with thrombolysis drugs within 48 hours of the study thrombolytic procedure.
  • Life expectancy less than (<) 1 year.
  • Body Mass Index (BMI) greater than (>) 40 kilograms/square meter (kg/m^2) or per Investigator's discretion participant is able tolerate the procedure and be compliant with post-procedure increased physical activity.
  • No flow in popliteal vein on duplex imaging
  • Thrombus extending ≥ 3 centimeters (cm) into the inferior vena cava (IVC). If central venous occlusion, consider computed tomography (CT) or magnetic resonance venography (MRV). For participants with bilateral DVT, it is recommended that central imaging be performed prior to treatment to evaluate the status of the IVC.
  • Active bleeding, recent (<3 months) gastrointestinal (GI) bleeding, active peptic ulcer, severe liver dysfunction, and bleeding diathesis.
  • Recent (<3 months) internal eye surgery or hemorrhagic retinopathy; recent (<10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation (CPR), obstetrical delivery, or other invasive procedure.
  • History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, or aneurysm.
  • Active cancer (metastatic, progressive, or treated within the last 6 months). Participants with non-melanoma primary skin cancers are eligible to participate in the study.
  • Hemoglobin <9.0 milligrams/deciliter (mg/dL) within 24 hours prior to the procedure
  • International normalized ratio (INR) ≥1.5 nanograms/deciliter (ng/dL) within 24 hours prior to the procedure.
  • Platelet count <100,000 cells/cubic millimeter (cells/mm^3) or >700,000 cells/mm^3 within 24 hours prior to the procedure.
  • Creatinine outside the normal range for the treating institution and considered clinically significant by the Investigator.
  • Uncontrolled hypertension, defined as systolic >175 millimeters of mercury (mmHg) and a diastolic >110 mmHg.
  • Use of clopidogrel, ticlopidine, or other thienopyridine antiplatelet drug within 7 days of the study procedure.
  • In the judgment of the clinician, the participant is at high risk for catastrophic bleeding.
  • Impossibility or refusal to give informed consent

结局指标

主要结局

Clinical Severity Scores

时间窗: up to 12 months

Improvement of Clinical efficacy will be evaluated using the Villalta score

Major Bleeding

时间窗: 72 hours

Freedom from Fatal bleeding, Symptomatic bleeding in a critical area or organ,Bleeding causing a fall in hemoglobin level of 20gL

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Baccellieri Domenico

Principal Investigator

IRCCS San Raffaele

研究点 (1)

Loading locations...

相似试验